The purpose of this study is to evaluate the efficacy and safety of treatment with subcutaneous anifrolumab versus placebo in adult participants with systemic sclerosis. The target population for this study includes patients who meet the 2013鈥�
- Investigator
- Michael R Bubb
- Ages
- 18 Years - 70 Years
- Sexes
- All